Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

November 10, 2005 09:20 ET

Swiss Medica Announces The Launch Of The National Fibromyalgia Association's Awareness Campaign For O24 Fibromyalgia

TORONTO, ONTARIO--(CCNMatthews - Nov. 10, 2005) -

FIRST EVER NFA SEAL OF APPROVAL GRANTED TO O24 FIBROMYALGIA

Swiss Medica, Inc. (OTCBB:SWME) today announced the launch of a national awareness program by the National Fibromyalgia Association (NFA) for the Company's new patented, clinically tested O24 Fibromyalgia product which is now available in over 5,000 retail outlets in the United States. In part, this nationwide program announces the granting of the NFA's first ever Seal of Approval to O24 Fibromyalgia.

The national NFA campaign includes -

1. A news letter noting the NFA Seal of Approval for O24 Fibromyalgia will be sent this week to tens of thousands of people in the Fibromyalgia community.

2. The NFA will also be profiled in Parade Magazine on Sunday November 13. Parade is a national weekly publication with a circulation of 34,500,000.

3. An email alert to tens of thousands Fibromyalgia sufferers across the United States on announcing which retailers are carrying O24 Fibromyalgia.

4. An editorial product profile on O24 Fibromyalgia will appear in the December edition of the NFA's monthly magazine, Fibromyalgia Aware, a paid circulation publication received by more than 50,000 subscribers. The Fibromyalgia Aware magazine will also include two samples of O24 Fibromyalgia in each copy.

5. A distribution of 40,000 O24 Fibromyalgia product samples to more than 1,650 Fibromyalgia support groups across the United States during the first week of December.

6. The mailing of samples of O24 Fibromyalgia, and a letter from the National Fibromyalgia Association detailing the NFA Seal of Approval and the other attributes of the clinically tested O24 Fibromyalgia to more than 6,000 primary care physicians in the United States specializing in the diagnosis and treatment of Fibromyalgia.

It is anticipated that this NFA-led campaign will touch millions of people in the next two months.

O24 Fibromyalgia is the only focused Fibromyalgia product available in national retailers to specifically address the pain associated with the Fibromyalgia condition. US Patented O24 Fibromyalgia has been clinically-tested in a randomized double blind study and its effectiveness for Fibromyalgia pain was clinically shown to be very conclusive.

In assessing this aggressive marketing push to support the recent launch of O24 Fibromyalgia, Swiss Medica's President and Chief Operating Officer, Grant Johnson says, "These activities are indicative of the strategic moves the Company is making to align our various products with core users and leverage key influencers for chronic ailment solutions."

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica, Inc.
    Investor Relations Contact: David Jones
    (866) 485-4243
    or
    Fusion Communications
    Media Contact: Dean Mailey
    (604) 218-6767
    dean@fusioncom.ca